Jan 24-25, 2018

San Francisco, CA

Previous Speakers

Expand/Collapse

Jason Fleming
Professor Department of Surgical Oncology
MD Anderson Cancer Center

Day Two

Thursday January 26th, 2017

09.35 | Advancing Clinical Success through Optimized Preclinical Decision Making

Paul Diehl
Chief Operations Officer
Cellecta

Day Two

Thursday January 26th, 2017

12.00 | Sensitive and Comprehensive Genome-Wide Expression Profiling Directly from Total RNA

Leon Hall
Senior Scientific Director, Global Oncology
Crown Bioscience

Dr. Leon Hall recently joined Crown Bioscience and serves as the Senior Scientific Director, Global Oncology. Dr. Hall has over 15 years of preclinical rodent research experience, and has been an innovator in the humanized mouse space having led the commercialization of humanized immune system and liver models and their application in oncology, inflammation, and immunology. Leon was awarded his Bachelor’s degree from University of Guelph, Canada, in 1993, before returning to England where he attended the University of Leicester and obtained his Master’s in Molecular Biology and Toxicology in 1995, and his Ph.D. in Molecular Biology in 1998. After receiving postdoctoral training in the department of anesthesiology and neurosurgery at the University of California at Davis, he was promoted to Assistant Professor in 2003 and led the development of their spinal cord injury program. Moving to industry in 2005, Leon joined The Jackson Laboratory as a Study Director and led the development of the preclinical pharmacology service, expanding the program to include immunology, oncology, and neuroscience, and ultimately heading up the program as Director for Scientific Operations and Business Development leader. In 2013, Leon was recruited to Taconic Bioscience to develop their humanized mouse program, and ultimately was given responsibility for Taconic’s Global Scientific Development and Translational Discovery program, leading international R&D programs in humanized mouse and oncology preclinical model development, GEMMs, and microbiome model development.

Day One

Wednesday January 25th, 2017

10.05 | Preclinical Immunocompetent Models for Translational Research

Francis Lee
Independent Immunopharmacology Consultant -
Formerly Senior Research Fellow at BMS, Bristol-Myers Squibb

Day One

Wednesday January 25th, 2017

17.05 | Chair’s Closing Remarks

09.00 | Chair’s Opening Remarks

Day Two

Thursday January 26th, 2017

15.00 | Chairman’s Closing Remarks

09.00 | Chair’s Opening Remarks

James Keck
Senior Director for the Clinical Lab & In Vivo Pharmacology Services
The Jackson Laboratory

Workshop A

Tuesday January 24th 2017

08.00 | Guide: Humanized Mice for Immuno-Oncology

Monte Winslow
Assistant Professor Departments of Genetics & Pathology
Stanford University School of Medicine

Day Two

Thursday January 26th, 2017

14.30 | In Vivo Cancer Modeling with Somatic Genome Editing

Angie Park
Senior Director, Immunotherapy & Stem Cell Biology
OncoMed Pharmaceuticals

Day Two

Thursday January 26th, 2017

09.05 | DLL4 Blockade Impacts Tumor Growth by Multiple Distinct Mechanisms

Saad Kenderian
Assistant Professor of Medicine & Oncology
Mayo Clinic

Workshop C

Tuesday January 24th 2017

15.00 | Improving the Development, Use & Value Extracted from the Latest Humanized Mouse Model Strains for Ex Vivo Therapies

Day One

Wednesday January 25th, 2017

14.05 | Preclinical Modeling of Chimeric Antigen Receptor T Cell Therapy and Combination Immunotherapy

Blythe Sather
Senior Scientist, Early Pipeline Research
Juno Therapeutics

Day Two

Thursday January 26th, 2017

14.00 | Identifying Assays for Screening CAR Constructs for Optimal Clinical Efficacy

Maria Costa
Principal Scientist
Rinat- Pfizer

Workshop B

Tuesday January 24th 2017

11.30 | Developing Preclinical Modeling Strategies for Cancer Immunotherapy Combinations

Day One

Wednesday January 25th, 2017

11.35 | Characterization of Preclinical Mouse Models of Cancer for Effective Targeting of Immune-Suppressive Microenvironment

Shraddha Sadekar
Senior Scientist, Translational PKPD, DMPK & Disposition
Merck

Day One

Wednesday January 25th, 2017

14.35 | Evaluation of Tumor Models: A Quantitative Analysis

Neal Goodwin
Vice President Corporate Research Development
Champions Oncology

Day One

Wednesday January 25th, 2017

12.05 | Advanced PDX Tumor Biology Platforms for Drug Advancement

Blake Aftab
Director of Preclinical & Translational Science
Atara Biotherapeutics

Shon Green
Scientist, Preclinical Development
Eureka Therapeutics

Day Two

Thursday January 26th, 2017

13.30 | Optimizing In Vivo Models for Developing CAR-T Therapies

Andrew Rhim
Associate Director for Translational Research
MD Anderson Cancer Center

Day One

Wednesday January 25th, 2017

15.05 | Developing Preclinical Models to Predict Clinical Outcomes for Immunotherapy Combination Therapies

Mari Suominen
Research Director
Pharmatest

Day Two

Thursday January 26th, 2017

10.05 | Rationale for Testing Anti-Cancer Drug Efficacy in the Bone Microenvironment

Selva Sukumar
Associate Principal Scientist
Merck

Day Two

Thursday January 26th, 2017

11.30 | Mechanistic Biomarkers and Translational Models for Optimizing Patient Stratification in Cancer Immunotherapies

Barbara Joyce-Shaikh
Associate Principal Scientist, Immunoncology
Merck Research Laboratories

Barbara Joyce-Shaikh completed her B.S in with Molecular Biology at San Jose State University. She has more than 20 years of biotech industry experience specializing in translational systems of immune function and immunoncology. Her work has contributed several patents as well as  medical literature published in journals such as Nature, Immunity, Nature Medicine, and the Journal of Experimental Medicine. She is currently a Project Leader in the Discovery Immunoncology group at Merck Research Laboratories, Palo Alto (Formerly DNAX Research Institute).  Her current research utilizes humanized mouse systems  and is focused on understanding how tumor stroma and immune cell interactions can be altered  with  novel immunomodulatory agents in different cancers. 

Day One

Wednesday January 25th, 2017

09.05 | Humanized Mouse Models for Drug Discovery Research

Michael Brehm
Assistant Professor
University of Massachusetts Medical School

Dr. Brehm received his Ph.D. from the Department of Microbiology and Immunology at the Pennsylvania State University College of Medicine. He is currently an Assistant Professor in the Program in Molecular Medicine at the University of Massachusetts Medical School and a member of the UMass Diabetes Center of Excellence. Dr. Brehm’s research program is focused on understanding how human effector T cells are regulated, and his laboratory is actively using “humanized” mice to model human T cell responses. Dr. Brehm has published over 80 manuscripts and reviews and is supported by funding from the JDRF, NIAID, NIDDK and the Helmsley Charitable Trust.

Workshop A

Tuesday January 24th 2017

08.00 | Guide: Humanized Mice for Immuno-Oncology

Joshua Breunig
Assistant Professor, Board of Governors Regenerative Medicine Institute
Department of Biomedical Sciences, Cedars-Sinai Medical Center

Day One

Wednesday January 25th, 2017

09.35 | Immunocompetent Somatic Transgenic Tumor Models (iSTTMs) for Preclinical Brain Tumor Research

David Grass
Senior Director, Genetic Engineering
Transgenic Genotyping & Reproductive Sciences, The Jackson Laboratory

Day Two

Thursday January 26th, 2017

11.00 | Mouse Models to Evaluate Developing Immune Therapies